

OPEN One-Pot Radiosynthesis and **Biological Evaluation of a Caspase-3** Selective 5-[123,125]iodo-1,2,3triazole derived Isatin SPECT Tracer

Matthias Glaser^{1,2}, Vineeth Rajkumar³, Seckou Diocou³, Thibault Gendron ^{1,2}, Ran Yan⁴, Pak Kwan Brian Sin¹, Kerstin Sander^{1,2}, Laurence Carroll⁵, R. Barbara Pedley³, Eric O. Aboagye⁵, Timothy H. Witney^{4,6} & Erik Arstad 10 1,2*

Induction of apoptosis is often necessary for successful cancer therapy, and the non-invasive monitoring of apoptosis post-therapy could assist in clinical decision making. Isatins are a class of compounds that target activated caspase-3 during apoptosis. Here we report the synthesis of the 5-iodo-1,2,3-triazole (FITI) analog of the PET tracer [18F]ICMT11 as a candidate tracer for imaging of apoptosis with SPECT, as well as PET. Labelling with radioiodine (123,125 I) was achieved in $55 \pm 12\%$ radiochemical yield through a chelator-accelerated one-pot cycloaddition reaction mediated by copper(I) catalysis. The caspase-3 binding affinity and selectivity of FITI compares favourably to that of [18 F]ICMT11 ($K_i = 6.1 \pm 0.9$ nM and 12.4 ± 4.7 nM, respectively). In biodistribution studies, etoposide-induced cell death in a SW1222 xenograft model resulted in a 2-fold increase in tumour uptake of the tracer. However, the tumour uptake was too low to allow in vivo imaging of apoptosis with SPECT.

Programmed cell death, also known as apoptosis, is a highly regulated biochemical process, required for tissue homeostasis, growth and embryonic development 1.2. Aberrant regulation of apoptotic cell death is a hallmark of a range of pathologies - from cancer, ischemia (stroke, myocardial infarction), autoimmunity, inflammation and neuro-degeneration, to allograft rejection and pathogenic infections3. In addition to (patho)physiological roles, apoptosis, necrosis or other recently described forms of cell death, such as necroptosis⁴, are the surrogate endpoint for most anticancer therapies⁵. Current methods used in the clinic to measure treatment efficacy rely on measuring changes in tumour size under the guidelines of the Response Evaluation Criteria in Solid tumours⁶. This approach, however, lacks sensitivity, and many weeks may elapse before there is evidence of tumour volume shrinkage. There is therefore a need to develop novel methods to non-invasively assess apoptotic cell death early after the initiation of therapy. The use of molecular imaging techniques, such as positron emission tomography (PET), and dynamic nuclear polarisation, has shown promise for monitoring of drug-induced cell death^{8,9}. Early radiolabelling studies concentrated on the measurement of cell membrane changes, such as the exposure of phosphatidylserine (PS) on the outer leaflet of the plasma membrane using annexin-V, a small 56 kDa protein^{10,11}. The poor pharmacokinetic profile of annexin V in humans, along with non-specific retention in viable tumour tissue has, however, precluded further clinical development of this radiotracer in its current form¹².

The current mechanistic model of apoptosis distinguishes between two converging extrinsic and intrinsic signalling pathways, via membrane death receptors and mitochondria, respectively¹³. Caspases (cysteine aspartyl-specific proteases) are essential for the intracellular transmission of the apoptotic signal. These enzymes can be classified either as initiators (caspases-2, -8, and -10), or effectors (caspases-3, -6, and -7)¹⁴. Due to its central role in the execution of the apoptotic pathway, it is caspase-3 expression that draws the main interest

¹Centre for Radiopharmaceutical Chemistry, University College London, 5 Gower Place, London, WC1E 6BS, United Kingdom. ²Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, United Kingdom. ³UCL, Cancer Institute, 72 Huntley Street, London, WC1E 6DD, UK. ⁴King's College London, School of Biomedical Engineering and Imaging Sciences, St. Thomas' Hospital, SE1 7EH, London, United Kingdom. 5 Imperial College London, Science, Technology & Medicine, Department of Medicine, Hammersmith Hospital, DuCane Road, London, W12 0NN, United Kingdom. ⁶Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom. *email: e.arstad@ucl.ac.uk

Previous Work

This Study

Isatin-Caspase-3 Pharmacophore

Cysteine binding site

S1-Pocket




Figure 1. Structures of selected caspase-3 binding PET radiotracers and pharmacophore model for binding interactions of isatins with caspase 3³⁴.

as a marker for targeted molecular imaging techniques^{7,15–17}. Various caspase-3 specific peptide tracers such as ¹⁸F-CP18^{18,19}, or ¹⁸F-C-SNAT⁸ have been described. The discovery of a non-peptidic caspase-3 inhibiting isatin analog has given rise to numerous radiolabelled tracers based on the isatin structural motif¹⁵. Figure 1 provides an overview of previously reported peptidic and isatin derived caspase-3 radiotracers^{20–27}. The isatin derived radiotracer ¹⁸F-ICMT-11 has shown particularly encouraging results in preclinical studies^{17,27–32}, and is the first of this class of tracers to have progressed to first-in-man imaging studies³¹.

According to the caspase-3 pharmacophore model (Fig. 1), the pyrrolidine sulfonamide moiety of isatin analogues is crucial for binding in the S2 hydrophobic pocket³³, while interactions of *N*-alkylated substituents with the S1 domain also contribute to binding affinity³⁴. The S1 binding domain was originally proposed to be a lipophilic pocket, due to the high affinities observed for isatin-derived ligands decorated with *N*-benzylic substituents. Subsequent studies revealed that 1,2,3-triazoles also provide favourable interactions with the S1 binding domain, as demonstrated by the high caspase-3 affinity observed for [¹⁸F]ICMT-11²⁷. This suggests that the S1 binding pocket encompasses both polar and lipophilic domains. We therefore speculated that addition of an iodine substituent to the triazole ring of ICMT-11 could further enhance the affinity by allowing for broader interactions within the S1 binding pocket. Motivated by the prospect of developing a high affinity caspase-3 selective SPECT tracer, herein we developed the 5-iodo-1,2,3-triazole derivative of ICMT-11. Furthermore, we also report the synthesis of ^{123/125}I-labelled analogues and their biological evaluation.

1

2

$$X = \frac{125}{123}$$
 $X = \frac{125}{127}$
 $X = \frac{125}{127}$
 $X = \frac{125}{127}$
 $X = \frac{125}{127}$

Figure 2. Reaction schemes. Synthesis of [$^{123/125/127}$ I]**FITI** and the negative control compound **4**. Reaction conditions: (**a**) 2-fluoroethyl azide, CuI, NEt₃, *N*-iodosuccinimide, MeCN, 3 h, r.t.; (**b**) 4 M HCl, MeCN, reflux, 1 h.; (**c**) [$^{123/125}$ I]NaI, bathophenanthroline/CuCl₂, NEt₃, 2-fluoroethyl azide, MeCN, 60 min, r.t.; (**d**) [125 I]NaI, bathophenanthroline/CuCl₂, 2-fluoroethyl azide, MeCN, 60 min, r.t.

Results and Discussion

Synthesis and radiolabelling. The non-radioactive reference compound, (S)-5-((2-((2,4-difluorophenoxy) methyl)pyrrolidin-1-yl)sulfonyl)-1-((1-(2- \underline{F} luoroethyl)-5-(\underline{I} odo)-1H-1,2,3- \underline{T} riazol-4-yl)methyl) \underline{I} ndoline-2,3-dione (referred to as FITI) was prepared in two steps. Treatment of the acetal protected isatin \underline{I}^{30} with 2-fluoroethyl azide³⁵ in the presence of copper(I) iodide, triethylamine and N-iodosuccinimide, according to a previously reported method for formation of iodotriazoles (Fig. 2)³⁶, gave the resulting 5-iodo-triazole $\underline{2}$. Subsequent deprotection with aqueous HCl afforded the target compound FITI in 64% overall yield. The alkyne $\underline{3}$ was obtained in 97% yield by alkylation of isatin with propargyl bromide. Subsequent reaction of $\underline{3}$ with 2-fluoroethyl azide and N-iodosuccinimide afforded the 5-iodo-1,2,3-triazole $\underline{4}$, which served as a negative control for biological assays.

Attempted labelling of FITI by reaction of the isatin 5 with [125 I]iodide in the presence of 2-fluoroethyl azide, using previously reported reaction conditions (60 °C, CuCl₂, Et₃N)³⁶, was unsuccessful and led to decomposition of the precursor 5. Eventually, we were able to resolve this problem by employing bathophenanthroline (BPhen) as a copper(I) chelator. We have previously shown that inclusion of bathophenanthrolinedisulfonate (BPDS) accelerates the copper(I) catalysed cyclisation reaction of 2-fluoroethyl azide with alkynes, and that it also can perturb side reactions by disrupting unfavourable interactions between copper(I) and other functional groups^{29,37}. Gratifyingly, this strategy also proved highly effective for the three-component click reaction, and in this case addition of BPhen to the labelling reaction allowed formation of [125 I]FITI from isatin 5 at room temperature within 1 h in >95% analytical yield as determined by HPLC. The isolated radiochemical yield after formulation was 55 \pm 12% (n = 8) with a radiochemical purity of >99%. The molar activity was >1.1 GBq/ μ mol. Figure 3 shows typical HPLC chromatograms of the crude labelling mixture, and [125 I]FITI after purification. The iodine-123 labelled analog [123 I]FITI was obtained in 51% (n = 2) decay corrected radiochemical yield after formulation with a radiochemical purity >99% and molar activity >4.3 GBq/ μ mol (based on the limit of UV signal quantification). The total time of radiosynthesis including formulation was 3 hours.

In vitro binding affinity. To determine the affinity of FITI for caspase-3 we used a commercially available enzyme kit, as previously described²⁷. ICMT-11 and the peptide inhibitor Ac-DVD-CHO³⁸ were included as positive controls, and the 5-iodo-1,2,3-triazole 4 used as a negative control for the assay. Unexpectedly, we were initially unable to obtain reproducible results with ICMT-11, which gave IC₅₀ readouts in the micromolar range. Systematic investigation of the assay conditions revealed that dithiothreitol (DTT), an additive present in the buffer supplied with the enzyme kit, rapidly reacted with ICMT-11 (incubation of ICMT-11 with the enzyme assay buffer led to its complete conversion to unknown products within 10 min at 40 °C as determined by HPLC). Consistent with this observation, the use of a DTT-free buffer (prepared according to Kopka et al.²² but without 2-mercaptoethanol) gave robust readouts from the assay (Fig. 4) with Ki values of 6.1 ± 0.9 nM and 12.4 ± 4.7 nM for FITI and ICMT-11, respectively. Caspase-8 was also included in the assay to evaluate the isoform selectivity, and for this enzyme no appreciable affinity was observed for FITI ($IC_{50} > 50 \,\mu\text{M}$ vs 6.3 nM for the peptide inhibitor Ac-IETD-CHO). The results from the enzyme assay are consistent with our hypothesis that the 5-iodo-1,2,3-triazole moiety can interact with both polar and lipophilic domains of the caspase-3 S1 binding pocket (Fig. 1). This is intriguing as the S1 pocket previously have been targeted with benzyl as well as a range of aryl groups, and our finding therefore raises the prospect of using trifunctionalized triazoles as highly flexible bioisosteres for one of the most commonly used motifs in medicinal chemistry.




Figure 3. HPLC Chromatograms. (a) Preparative HPLC profile of the reaction mixture following labelling of [¹²⁵I]FITI, showing residual [¹²⁵I]iodide (1), ICMT-11 (2), alkyne 5 (3), [¹²⁵I]FITI (4), and BPhen complex (5). (b) Analytical HPLC profile of [¹²⁵I]FITI after purification and formulation in saline/10% EtOH (v/v) (6) [NB: The HPLC systems used for (a) and (b) are different].

a IC₅₀ Profiles for Caspase-3 binding

b Binding Data for FITI and ICMT-11

% Rate	100 - 80 - 60 - 40 - 20 -	ICMTFITI	pound 4 F-11 EVD-CHO		•		•	•	`	
	1E-12	1E-11	1E-10	1E-9	1E-8	1E-7	1E-6	1E-5	1E-4	1E-3
				Inhibit	or Cond	centrati	on (M)			

	K _i Caspase-3	IC ₅₀ Caspase-8	logD
	(nM)	(nM)	
FITI	$\textbf{6.1} \pm \textbf{0.9}$	> 50,000	$\textbf{1.6} \pm \textbf{0.1*}$
ICMT-11	12.4 ± 4.7	> 5000 ²⁷	1.61 27
4	> 50,000	-	$\textbf{1.14} \pm \textbf{0.06*}$
Ac-DEVD-CHO	0.17 (0.23-2.239)	-	-
Ac-IETD-CHO	-	6.3	-

^{*} n=3, measured using 125 I-labelled compound, respectively

Figure 4. *In vitro* data. (a) IC $_{50}$ profiles for caspase-3 binding of FITI, ICMT-11, compound 4, and Ac-DEVD-CHO. Data for compound 4 and Ac-DEVD-CHO are averages of three experiments from one assay plate. Data for FITI and ICMT-11 are averages of three assay plates from three experiments each with standard deviations shown. (b) Table showing caspase-3 and caspase-8³⁹ binding data for FITI, ICMT-11 and compound 4.

Biodistribution studies. In exploratory *in vitro* studies we identified SW1222 as a promising cell line for imaging of drug induced apoptosis with etoposide. Biodistribution of [125 I]FITI was therefore determined in SW1222 tumour-bearing animals 60 min after *i.v.* tail vein injection in either etoposide-treated or control animals (Fig. 5). In control animals, the tracer showed high uptake in the small intestine ($48 \pm 13\%$ ID/g), stomach ($28 \pm 25\%$ ID/g) and liver ($17 \pm 6\%$ ID/g), and low uptake in the tumour ($0.7 \pm 0.4\%$ ID/g). The distribution profile suggest that clearance of [125 I]FITI was dominated by the hepatobiliary route. This is mirrored by the pre-clinical and first-in-man results with [18 F]ICMT- $11^{28,31}$. These data also indicate that de-iodination might not be the primary cause of increased intestinal uptake with [125 I]FITI, and may instead be due to caspase-3 expression in apoptotic intestinal cells.

Mice treated with a single dose of etoposide ($50 \, \text{mg/kg}$, $24 \, \text{hrs}$, i.p.) demonstrated significantly higher tumour levels of [^{125}I]FITI compared to control animals ($1.5 \pm 0.2 \, \text{vs} \, 0.7 \pm 0.4 \, \text{MID/g}$) (p < 0.001). However, the overall uptake in the tumour was too low to allow *in vivo* imaging of tumour apoptosis with SPECT. The biodistribution study did not reveal any other substantial changes in tracer uptake following etoposide treatment, although *in vivo* SPECT imaging showed marked changes in the abdominal distribution of FITI. It is unclear if this reflects drug induced apoptosis, or if the observed changes were due to swelling or increased local blood flow. Analysis of the mouse plasma following *i.v.* injection of [125 I]FITI indicated rapid metabolism with less than 50% intact parent tracer present 15 min post-injection (Fig. 5). A single polar radioactive metabolite was detected consistent with deiodination *in vivo* to give [125 I]iodide. However, it should be noted that a similar polar metabolite has been observed for the non-iodinated analog [18 F]ICM-11, and the low uptake in the thyroid ($2.4 \pm 1 \, \text{MID/g}$ at 60 min




Figure 5. Biology data. (a) *Ex vivo* biodistribution data for selected tissues in control and etoposide-treated mice 60 min after [125 I]FITI injection into SW1222 tumour-bearing mice. (b) HPLC profiles of mice plasma metabolite samples showing degradation of [125 I]FITI ($t_R = 22.3 \, \text{min}$). (c) SPECT/CT images of SW1222 tumour mice using [123 I]FITI. Control and etoposide treated mouse after 24h, the green circle indicates the location of the xenograft. Both animals have been injected with 5 MBq of [123 I]FITI.

post-injection) and high liver uptake point to another metabolic route. In any case, the rapid metabolism makes FITI poorly suited as a tracer for *in vivo* imaging of apoptosis.

Conclusions

We have prepared the 5-iodo-1,2,3-triazole analog of ICMT-11 as a putative dual SPECT and PET tracer for imaging of drug-induced apoptosis. The compound showed low nanomolar affinity for caspase-3, and increased potency as compared to ICMT-11. The results are consistent with our hypothesis that the 5-iodo-1,2,3-triazole moiety interacts with both polar and lipophilic domains of the caspase-3 S1 binding pocket. The radioiodinated tracer was obtained in 55% radiochemical yield using, for the first time, chelator-accelerated copper catalysed three-component click chemistry for preparation of 5-iodo-1,2,3-triazoles. Biological characterisation of the tracer showed increased tumour uptake in etoposide treated mice, as compared with the non-treated control group. However, low tumour uptake and rapid metabolism precludes the use of the tracer for imaging of tumour apoptosis *in vivo*.

Methods

All methods and data for synthetic chemistry, radiochemistry and biology are available in supporting information.

Chemistry. (S)-5-((2-((2,4-difluorophenoxy)methyl)pyrrolidin-1-yl)sulfonyl)-1-((1-(2-fluoroethyl)-5-iodo-1H-1,2,3-triazol-4-yl)methyl)indoline-2,3-dione (FITI). Alkyne 1 (25 mg, 54 μmol)²⁷ was dissolved in acetonitrile (500 μL). To the resulting solution were added copper(I) iodide (9 mg, 47 μmol), triethylamine (7 μL, 50 μmol), 2-fluoroethyl azide as a 0.5 M solution in THF (100 μL, 50 μmol), and N-iodosuccinimide (12 mg, 53 μmol). The mixture was stirred at room temperature for 3 hours. After evaporating the solvent using a stream of nitrogen, the residue was dissolved in ethyl acetate, filtered through Celite[®], and purified using column chromatography (SiO₂, 50% ethyl acetate in n-hexane). The resulting pure isolated fraction of intermediate 2 was re-dissolved in acetonitrile (2 mL) and a 4 M aqueous solution of hydrochloric acid (1 mL, 4 mmol) was added. The resulting mixture was heated to reflux for 1 h. After cooling to room temperature, the reaction mixture was diluted with water (25 mL) and the product was extracted with ethyl acetate (3 × 25 mL). The combined organic layers were dried over magnesium sulfate and the solvent was evaporated under reduce pressure to afford the tittle compound as a yellow crystals (21 mg, 62%); ¹H NMR (600 MHz, CDCl₃) δ (ppm): 8.05 (dd, ³J = 8.3 Hz, ⁴J = 1.9 Hz, 1 H, Ph-H6), 8.02 (d, ⁴J = 1.9 Hz, 1 H, Ph-H4), 7.49 (d, ³J = 8.3 Hz, 1 H, Ph-H7), 6.93 (td, J = 9.2 Hz, 5.2 Hz, 1 H, ArH), 6.84-6.77

 $\begin{array}{l} (\text{m, 2 H, A}rH), 5.06 \text{ (s, 2 H, -NC} \\ H_2\text{Triazole}), 4.86 \text{ (dt, }^2J_{\text{H-F}} = 46 \text{ Hz, }^3J = 5.1 \text{ Hz, 2 H, Triazole-CH}_2\text{C}\\ H_2\text{F}), 4.69 \text{ (dt, }^3J_{\text{H-F}} = 24 \text{ Hz, }^3J = 5.1 \text{ Hz, 2 H, Triazole-C}\\ CH_2\text{C}\\ H_2\text{F}), 4.20 \text{ (dd, }J = 9.2 \text{ Hz, 3.1 Hz, 1 H, }H14_{\tiny \alpha}), 3.99 - 3.95 \text{ (m, 1 H, }H14_{\tiny \beta}), 3.94 - 3.92 \text{ (m, 1 H, }H13), 3.50 - 3.52 \text{ (m, 1 H, Pyrro-}\\ H_2\text{eq}), 3.13 - 3.17 \text{ (m, 1 H, Pyrro-}\\ H_2\text{ax}), 2.08 - 1.98 \text{ (m, 2 H, Pyrro-}\\ H_3,4_{\tiny \text{ax}}), 1.82 - 1.73 \text{ (m, 2 H, Pyrro-}\\ H_3,4_{\tiny \text{eq}}); {}^{13}\mathbf{C} \mathbf{NMR} \text{ (150 MHz, CDCl}_3) \\ \delta \text{ (ppm): 181.5 (C), 157.2 (C), } 156.7 \text{ (dd, }J_{\text{C-F}} = 242 \text{ Hz, 10 Hz, C}), 153.1 \text{ (C), 152.3 (dd, }J_{\text{C-F}} = 249 \text{ Hz, 11 Hz, C}), 145.6 \text{ (C), 143.1 (dd, }J_{\text{C-F}} = 10 \text{ Hz, 3 Hz, C}), 137.6 \text{ (CH), 133.9 (C), 124.4 (CH), 117.5 (C), 115.5 (dd, }J_{\text{C-F}} = 9 \text{ Hz, 2 Hz, CH}), 112.5 \text{ (CH), 110.6 (dd, }J_{\text{C-F}} = 22 \text{ Hz, 5 Hz, CH}), 105.0 \text{ (dd, }J_{\text{C-F}} = 27 \text{ Hz, 22 Hz, CH}), 81.2 \text{ (C), 81.1 (d, }J_{\text{C-F}} = 172 \text{ Hz, CH}_2), 71.6 \text{ (CH}_2), 58.7 \text{ (CH), 51.0 (d, }J_{\text{C-F}} = 22 \text{ Hz, CH}_2), 49.6 \text{ (CH}_2), 36.2 \text{ (CH}_2), 29.0 \text{ (CH}_2), 24.2 \text{ (CH}_2); \textbf{m.p.: }163-165 \text{ °C; }\textbf{HRMS (ESI): }[\text{M}+\text{H}]^+ \text{ Calcd. m/z }676.0339, \text{ found m/z }676.0359. \end{array}$

Radiochemistry. Radiolabelling of $[^{123}, ^{125}I]FITI$. To a suspension of copper(II) chloride (134 µg, 1.0 µmol) in anhydrous acetonitrile (20 µL) and triethylamine (151 µg, 1.5 µmol) was added a solution of bathophenanthroline (BPhen) (33 μg, 0.1 μmol) in anhydrous acetonitrile (20 μL). A solution of the isatin alkyne 5 (460 μg, 1.0 μmol) in anhydrous acetonitrile (20 µL) was subsequently added and the mixture was left for 5 min at room temperature. *NB: The isatin alkyne/CuCl*₂/bathophenanthroline/triethylamine complex in acetonitrile must be freshly prepared and used immediately. Otherwise, the reaction will not work, or give low RCY. The resulting solution was added to aqueous [1251] NaI (1-37 MBq, 6.0 µL) in a polypropylene (PP) centrifuge tube (1.5 mL) immediately followed by a stock solution of 2-fluoroethyl azide in anhydrous acetonitrile (40 mM, 25 µL, 1 µmol). The tube was kept at room temperature with occasional agitation for 60 min. The reaction mixture was diluted with a solution of acetonitrile and water (0.5 mL, 3:2 v/v). The resulting solution was purified by HPLC on a ZORBAX® column (300SB-C18, 5 µm, 9.4 × 250 mm, Agilent) using water and methanol, each containing 0.1% TFA (gradient elution with a flow rate of 3 mL/min, from 40% to 55% methanol content over 50 min, then from 55% to 90% methanol content over 5 min; Fig. 3, $R_t \approx 54$ min). The collected fraction was diluted with water (5 mL), and loaded on a conditioned Sep-Pak tC18 Plus Light Cartridge. After washing with water (5 mL) and drying with air (15 mL), the cartridge was eluted with EtOH (0.5 mL). The product was collected in fractions (0.1 mL). The fractions containing >90% of radioactivity (typically fractions 2 and 3) were combined and diluted with saline to give an EtOH content of < 10% (v/v). The final sample was obtained with a radiochemical yield of $55 \pm 12\%$ (n = 8) and a radiochemical purity of >99%. The iodine-123 labelled analog was obtained using an otherwise identical procedure with the exception that aqueous [123I]NaI (6 µL, 48-132 MBq) was used. The target compound [123I]FITI was obtained in a decay-corrected radiochemical yield of 51% (n=2), and with a radiochemical purity >99%.

Biology. Caspase enzyme inhibition assay. Recombinant human caspase-3 and caspase-8 enzymes, substrates Ac-DEVD-AMC and Ac-IETD-AMC, and inhibitors Ac-DEVD-CHO and Ac-IETD-CHO were purchased from Enzo Life Sciences AG. The assay buffer was consisted of HEPES (pH 7.4, 20 mM), sucrose (10%), NaCl (100 mM), CHAPS (0.1%), and EDTA (2 mM). A Varioskan-LUX (ThermoFisher UK) fluorescence plate reader was used to read 96-well plates in triplicate at 37 °C incubation temperature (excitation wavelength = 355 nm, emission wavelength = 460 nm). The inhibitor test compounds were serially diluted in DMSO (1 mM, 0.1 mM, 10 μM, 1 μM, 0.1 μM, 10 nM, 1 nM, and 0.1 pM). The caspase enzyme stock solutions were made up to give 1 U per well. The substrates were prepared in assay buffer solution (40 μM). Inhibitor solution (5 μL) was added to wells containing assay buffer (20 μL) followed by substrate solution (50 μL). After an incubation period at 37 °C for 10 min, the enzyme solution was added (25 μL). The wells of the blank experiments contained assay buffer (50 μL) and substrate solution (50 μL). The control wells used assay buffer (20 μL), enzyme solution (25 μL), substrate (50 μL), and DMSO (5 μL). Fluorescence signals were measured once per minute for one hour. The IC50 values were computed based on the linear ranges of the dynamic signal profiles using non-linear correlation software (OriginPro 2015). The Ki values were calculated from an average of three IC50 measurements using the Cheng-Prusoff equation and a Km for Ac-DEVD-AMC of 9.7 μM.

Biodistribution studies in tumour-bearing mice. Biodistribution studies in tumour-bearing mice were carried out using female NOD scid-gamma (NSG) mice (6–8 weeks old, 20–25 g) bred in the UCL animal facility. For all studies mice were acclimatized for a week prior to initiation of studies. Mice were housed under sterile conditions in individually ventilated cages, fed with standard chow diet and water ad libitum and maintained on an automatic 12 h light cycle at 22–24 °C. All animal experiments were performed in accordance with the UK Home Office Animals Scientific Procedures Act 1986 and United Kingdom Co-ordinating Committee on Cancer Research Guidelines for the Welfare and Use of Animals in Cancer Research, and were approved by the University College London Animal Ethics Committee. Subcutaneous tumours were established in female NSG mice using human colorectal adenocarcinoma cell line SW1222 cells. Briefly, 5×106 cells were injected into the right flank of mice and allowed to grow to a volume of 0.3–0.5 cm³. Tumour volumes were calliper-measured and calculated using the formula: volume = $4\pi/3$ (1/2 length \times 1/2 width \times 1/2 height). Tumours were sized-matched and animals were either untreated or treated with a single dose of clinically formulated etoposide 24 h before radiotracer injection (Eposin, 50 mg/kg, i.p.).

Plasma metabolite analysis. Blood (0.7–1.0 mL) was removed from BALB/c mice shortly after the animals were euthanized and was spun down in a micro-centrifuge at 13,000 rpm for 3 min. The supernatant was decanted and mixed with ice-cold MeCN (1.0 mL) followed by vortexing (1 min) and centrifugation (13,000 rpm, 3 min). The supernatant was diluted with water (1.0 mL) and analyzed by HPLC on a ZORBAX® column (300SB-C18, 5 μ m, 9.4 × 250 mm, Agilent) using water and methanol, each containing 0.1% TFA (gradient elution with a flow rate of 3 mL/min, hold 1 min at 10% methanol content and then from 10% to 90% methanol content over 20 min).

SPECT-CT imaging of [123I]FITI in SW1222 tumour-bearing mice. The mice were anesthetised by inhalation of 2% isoflurane in oxygen, injected intravenously via the tail vein with 5 MBq of [123I]FITI, and imaged with a NanoSPECT/CT small animal imager (Mediso Imaging Systems, Budapest, Hungary) for 2 h using a multi-pinhole (nine pinholes, aperture 1.0 mm collimator and a transaxial FOV of 62 mm). Single photon emission computed tomography images were reconstructed using Hi SPECT software and a dedicated ordered subset-expectation maximisation algorithm (Scivis, Goettingen, Germany).

Statistical analysis. Data are expressed as mean \pm SD and comparison between 2 datasets was determined using the Student t test (Prism v6.0 software, GraphPad). Results were considered as statistically significant at a p-value of \leq 0.05.

Data availability

All data generated or analysed during this study are included in this published article and the Supplementary Information.

Received: 3 September 2019; Accepted: 26 November 2019;

Published online: 17 December 2019

References

- Renehan, A. G., Booth, C. & Potten, C. S. What is apoptosis, and why is it important? Br. Med. J. 322, 1536–1538, https://doi. org/10.1136/bmj.322.7301.1536 (2001).
- Denault, J. B. & Salvesen, G. S. Caspases: Keys in the ignition of cell death. Chem. Rev. 102, 4489–4499, https://doi.org/10.1021/cr010183n (2002).
- 3. Reed, J. C. Apoptosis-based therapies. Nature Reviews Drug Discovery 1, 111-121, https://doi.org/10.1038/nrd726 (2002).
- 4. Lalaoui, N. & Brumatti, G. Relevance of necroptosis in cancer. Immunol. Cell Biol. 95, 137–145, https://doi.org/10.1038/icb.2016.120
- 5. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. *Nature* 411, 342–348, https://doi.org/10.1038/35077213 (2001).
- 6. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247, https://doi.org/10.1016/j.ejca.2008.10.026 (2009).
- 7. Neves, A. A. & Brindle, K. M. Imaging cell death. J. Nucl. Med. 55, 1-4 (2014).
- 8. Witney, T. H. et al. A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment. Clin. Cancer Res. 21, 3896–3905, https://doi.org/10.1158/1078-0432.CCR-14-3176 (2015).
- 9. Witney, T. H. *et al.* A Comparison between Radiolabeled Fluorodeoxyglucose Uptake and Hyperpolarized C-13-Labeled Pyruvate Utilization as Methods for Detecting Tumor Response to Treatment. *Neoplasia* 11, 574–U588, https://doi.org/10.1593/neo.09254 (2009)
- 10. Zijlstra, S., Gunawan, J. & Burchert, W. Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl. Radiat. Isot. 58, 201–207 (2003).
- 11. Li, X. H. et al. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjugate Chem. 19, 1684–1688 (2008).
- 12. Reshef, A., Shirvan, A., Akselrod-Ballin, A., Wall, A. & Ziv, I. Small-molecule biomarkers for clinical PET imaging of apoptosis. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine* 51, 837–840 (2010).
- 13. Fox, J. L. & MacFarlane, M. Targeting cell death signalling in cancer: minimising 'Collateral damage'. Br. J. Cancer 115, 5–11, https://doi.org/10.1038/bjc.2016.111 (2016).
- Clark, A. C. Caspase Allostery and Conformational Selection. Chem. Rev. 116, 6666-6706, https://doi.org/10.1021/acs.chemrev.5b00540 (2016).
- 15. Poreba, M. et al. Small Molecule Active Site Directed Tools for Studying Human Caspases. Chem. Rev. 115, 12546–12629, https://doi.org/10.1021/acs.chemrev.5b00434 (2015).
- Smith, B. A. & Smith, B. D. Biomarkers and molecular probes for cell death imaging and targeted therapeutics. *Bioconj. Chem.* 23, 1989–2006 (2012).
- 17. Nguyen, Q. D., Challapalli, A., Smith, G., Fortt, R. & Aboagye, E. O. Imaging apoptosis with positron emission tomography: 'Bench to bedside' development of the caspase-3/7 specific radiotracer [18F]ICMT-11. Eur. J. Cancer 48, 432–440 (2012).
- 18. Doss, M. et al. Biodistribution and Radiation Dosimetry of 18F-CP-18, a Potential Apoptosis Imaging Agent, as Determined from PET/CT Scans in Healthy Volunteers. J. Nucl. Med. 54, 2087–2092, https://doi.org/10.2967/jnumed.113.119800 (2013).
- 19. Su, H. et al. Evaluation of [18F]-CP18 as a PET imaging tracer for apoptosis. Mol. Imag. Biol. 15, 739-747 (2013).
- 20. Zhou, D. et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg. Med. Chem. Lett. 16, 5041-5046 (2006).
 21. Zhou, D. et al. [F-18]- and [C-11]-Labeled N-benzyl-isatin sulfonamide analogues as PET tracers for Apoptosis: synthesis,
- 21. Zhou, D. et al. [F-18]- and [C-11]-Labeled N-benzyl-isatin sulfonamide analogues as PET tracers for Apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [C-11]WC-98. Organic & Biomolecular Chemistry 7, 1337–1348, https://doi.org/10.1039/B819024k (2009).
- 22. Kopka, K. et al. 5-Pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis. J. Med. Chem. 49, 6704–6715 (2006).
- Podichetty, A. K. et al. Fluorinated Isatin Derivatives. Part 2. New N-Substituted 5-Pyrrolidinylsulfonyl Isatins as Potential Tools for Molecular Imaging of Caspases in Apoptosis. J. Med. Chem. 52, 3484

 –3495 (2009).
- Faust, A. et al. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[F-18]fluoroethoxy)benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Im 51, 67-73 (2007).
- Chen, D. L. et al. Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. Nucl. Med. Biol. 36, 651–658 (2009).
- Waldmann, C. M. et al. Novel fluorine-18 labeled 5-(1-pyrrolidinylsulfonyl)-7-azaisatin derivatives as potential PET tracers for in vivo imaging of activated caspases in apoptosis. Bioorg. Med. Chem. 23, 5734–5739, https://doi.org/10.1016/j.bmc.2015.07.014 (2015).
- 27. Smith, G. et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F] fluoroethylazide. J. Med. Chem. 51, 8057-8067 (2008).
- 28. Nguyen, Q. D. et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc. Natl. Acad. Sci. USA 106, 16375–16380 (2009).
- Glaser, M. et al. Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation. Bioorg. Med. Chem. Lett. 21, 6945–6949 (2011).

- 30. Fortt, R., Smith, G., Awais, R. O., Luthra, S. K. & Aboagye, E. O. Automated GMP Synthesis of [F-18]ICMT-11 for *In Vivo* Imaging of Caspase-3 Activity. *Nucl. Med. Biol.* 39, 1000–1005, https://doi.org/10.1016/j.nucmedbio.2012.03.004 (2012).
- Challapalli, A. et al. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J. Nucl. Med. 54, 1551–1556 (2013).
- 32. Witney, T. H., Fortt, R. R. & Aboagye, E. O. Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by F-18-ICMT-11-Positron Emission Tomography. *Plos One* 9, https://doi.org/10.1371/journal.pone.0091694 (2014).
- 33. Lee, D. et al. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J. Biol. Chem. 275, 16007–16014, https://doi.org/10.1074/jbc.275.21.16007 (2000).
- 34. Limpachayaporn, P. et al. Synthesis, 18F-radiolabeling, and in vivo biodistribution studies of N-fluorohydroxybutyl isatin sulfonamides using positron emission tomography. J. Med. Chem. 56, 4509–4520 (2013).
- Glaser, M. & Årstad, E. 'Click labeling' with 2-[18F] fluoroethylazide for Positron Emission Tomography. Bioconjugate Chem. 18, 989-993 (2007).
- 36. Yan, R. et al. A One-Pot Three-Component Radiochemical Reaction for Rapid Assembly of ¹²⁵I-Labeled Molecular Probes. J. Am. Chem. Soc. 135, 703–709, https://doi.org/10.1021/Ja307926g (2013).
- 37. Galante, E., Schoultz, B. W., Koepp, M. & Årstad, E. Chelator-accelerated one-pot 'Click' labeling of small molecule tracers with 2-[18F] fluoroethyl azide. *Molecules* 18, 5335–5347 (2013).
- Nicholson, D. W. et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37–43 (1995).
- 39. Ekert, P. G., Silke, J. & Vaux, D. L. Caspase inhibitors. Cell Death Differ. 6, 1081-1086 (1999).

Acknowledgements

The authors would like to thank Vincent Gray, Mathew Robson, and Tammy Kalber for their expert technical support. This work was supported by CRUK & EPSRC Comprehensive Cancer Imaging Centre at KCL, UCL & Imperial jointly funded by Cancer Research UK and the Engineering and Physical Sciences Research Council (EPSRC; C1519/A16463; C2536/A10337) (M.G., T.G. and L.C.), and an EPSRC Case Studentship in partnership with GE (P.K.B.S.). T.H.W. was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 107610/Z/15/Z). This work was undertaken at UCLH/UCL, which is funded in part by the Department of Health's NIHR Biomedical Research Centres funding scheme.

Author contributions

M.G. (Radiochemistry, preparation of the radiotracer for biological studies, *in vitro* biology, preparation of manuscript), V.R. (*In vitro* and *in vivo* biology studies, preparation of manuscript, S.D. (*In vitro* assays), T.G. (Synthetic chemistry, technical support, preparation of manuscript), R.Y. (Radiochemistry method development, preparation of manuscript), P.K.B.S. (Synthetic chemistry, preparation of manuscript), K.S. (Experimental design and facility support), L.C. (synthetic chemistry), R.B.P. (Design of biological studies, provided funding and facility support), E.O.A. (Design of biological studies, provided funding and reviewed manuscript), T.H.W. (Enzyme assay design and analysis, preparation of manuscript) and E.A. (Principal investigator, conceptual design of radiochemistry and biological studies. Provided funding, facility support and prepared manuscript).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-55992-0.

Correspondence and requests for materials should be addressed to E.Å.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019